ALPI-Related Inflammatory Bowel Disease (Monogenic IBD): A Patient Guide

Inflammatory Bowel Disease (IBD) is usually a complex puzzle involving interacting genetic, microbial, and immune factors. However, for a very small number of families, the cause is much more direct. ALPI-related Inflammatory Bowel Disease is a “monogenic” condition, meaning it is caused by pathogenic variants in a single gene called ALPI ^[1]. This gene is the blueprint for intestinal alkaline phosphatase (IAP), a specialized enzyme that helps regulate the gut barrier ^[2]. When this blueprint is altered, the gut loses some of its ability to dephosphorylate common bacterial products, which is proposed to contribute to continuous inflammation ^[1].

The absence of this enzyme essentially leaves the intestinal “border” unguarded. In a healthy body, IAP patrols the gut lining and reduces inflammatory molecules produced by normal gut bacteria ^[3]. Without this defense, these molecules can trigger the immune system’s alarm bells, contributing to the severe diarrhea, pain, and weight loss characteristic of early-onset IBD ^[1]. Because the bacterial products themselves remain in the gut, the inflammation can be exceptionally stubborn and difficult to manage with standard medications ^[4].

What is Known and What is Uncertain
It is important to know that the evidence base for ALPI-related IBD is exceptionally small—the foundational report identified only two unrelated patients—so disease course and treatment response remain uncertain ^[1]. Living with an ultra-rare diagnosis means the symptoms can vary significantly depending on when they first appear. In very young children, the disease has been reported to present as a severe, total-colon inflammation that can even mimic celiac disease ^[1]. In teenagers, it may look more like Crohn’s disease, sometimes involving complications like joint swelling or intestinal blockages ^[1]. Because these symptoms are shared with many other conditions, a definitive molecular diagnosis generally depends on identifying pathogenic “biallelic” variants—meaning one altered copy inherited from each parent—and a compatible clinical picture ^[5].

Because this condition involves a specific genetic variant, it often requires a highly specialized approach to care. Standard IBD medications like steroids and biologics are often tried first but may not provide long-term relief ^[1]. This makes specialized nutritional support and, in some cases, individualized surgery (such as removing an inflamed section of the bowel) important options for specific complications ^[6]. While researchers are currently exploring ways to replace the missing enzyme directly in animal models and other conditions, the focus of care remains on protecting the intestinal barrier and ensuring you or your child can thrive despite the challenges of an ultra-rare condition ^[7][5].